<?xml version="1.0" encoding="UTF-8"?>
<p id="Par22">AGAs have been found in systemic lupus erythematosus (SLE) patients with neuropsychiatric manifestations of the disease. In particular, anti-GM1 antibodies were associated with neuropsychiatric manifestations, highlighting their predictive and, potentially, prognostic value.
 <sup>
  <xref ref-type="bibr" rid="CR66">66</xref>,
  <xref ref-type="bibr" rid="CR67">67</xref>
 </sup> Also celiac disease (CD), which can have a variety of neurological manifestations, e.g cerebellar ataxia, peripheral neuropathy, epilepsy and depression
 <sup>
  <xref ref-type="bibr" rid="CR68">68</xref>,
  <xref ref-type="bibr" rid="CR69">69</xref>
 </sup>, has been associated with anti-GM1 antibodies.
 <sup>
  <xref ref-type="bibr" rid="CR70">70</xref>
 </sup> The trigger that induces the generation of AGAs is not known. However, it is possible that the formation of complexes between gliadin and GM1 leads to the generation of anti-GM1 antibodies as a “side product”.
 <sup>
  <xref ref-type="bibr" rid="CR71">71</xref>,
  <xref ref-type="bibr" rid="CR72">72</xref>
 </sup> AGAs have also been found in patients with type 1 diabetes but their correlation with the development of diabetic neuropathy has not been confirmed.
 <sup>
  <xref ref-type="bibr" rid="CR73">73</xref>,
  <xref ref-type="bibr" rid="CR74">74</xref>
 </sup>
</p>
